8 technologies match your search results :
Save the technology that interests you
You can save the technologies you're interested with in a selection list. To do this, click on the add button. You can then access this Wishlist, to view it, share it, or send it by mail.
Potent Mn contrast agent ligand used for MRI. We develop Bispidine-based Mn2+ contrast agents with higher stability and relaxivity than standards, providing a safer alternative to Gadolinium contrast agents.
Small molecule (NCE) agonist of sigma1 receptor for the treatment of several neurodegenerative diseases. 2 chemical series, protected by 2 patents, highly selective and affine. Preliminary in-vivo data available on Alzheimer's, ALS (amyotrophic lateral sclerosis) and CIAS (cognitive impairement associated with schizophrenia) models.
New gene therapy to treat Fragile X syndrome by targeting DGKk, new innovative therapeutic target validated in human tissues by the research team. We generated a first in-vivo proof of concept of DGKk gene therapy and patented the approach.
New antibody fragments for the treatment of thrombosis (stroke, thrombotic purpura, coronary syndrome...). Our approach is directed against a platelet receptor that is not currently targeted by commercially available products, and prevents thrombus formation with a reduced bleeding risk.
Human monoclonal antibodies with great neutralizing properties against BK virus. BKV infection causes BKV-associated nephropathy (BKVAN) in kidney transplant recipients, which leads to graft loss or urothelial carcinoma, but can also lead to hemorrhagic cystitis in bone marrow transplant recipients. Our lead antibodies have the ability to be best in class and neutralize BKV with improved efficacy.
New target and approach for the treatment of melanoma. Our technology aims at decreasing the expression of a novel long non-coding RNA that has been shown to be essential for the survival and proliferation of melanoma cancer cells using antisense oligonucleotides.
Development of a microfabricated substrate which allows the production of reproducible organoids.
Cell plates with cavities which contain equal numbers of cells which grow similarly:
- Low size variability of cysts
- High circularity of cysts
- High reproducibility of drug screening
- Better readout for more robust results
New Chemical Entity with neutraligand activity on CXCL12
New way to modulate Immune response and inflammation in various clinical settings, including auto-immune diseases and inflammatory pain.
Sub-micromolar affinity, promising in-vitro ADME parameters and oral bioavailability.
No time to search for the perfect opportunity?
Tell us about you, and we'll do it for you! Go
Entrepreneurs, Researchers:
they testify
